COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Ascletis Pharma Inc.
The FDA cleared the IND application to start Phase 1 study of ASC11 in COVID-19 patients- reported on Nov.23, 2022.

Investigational New Drug (IND) application for ASC11 was filed to the FDA- reported on Nov.1, 2022.
Tevogen Bio
TVGN-489- to treat Covid-19
None of the patients in the TVGN 489 Proof-of-Concept trial, treated for their initial COVID infection, developed Long COVID. Tevogen plans to explore the potential of TVGN 489 to also treat Long COVID- reported on Nov.22, 2022.

Proof-of-Concept study of TVGN-489 in high-risk COVID-19 patients has advanced to the fourth and final dose levels-reported on June 7, 2022.
JCHX-221-Covid-19 vaccine candidate
IND clearance to conduct Phase 1/2 study of JCHX-221 was received from the FDA-reported on Nov 21, 2022.
Phase 2 study of temelimab for the treatment of long-COVID was initiated- reported on Nov.16, 2022.
CanSino Biologics Inc.
Convidecia Air-Inhaled COVID-19 Vaccine
The National Medical Products Administration of China approved Convidecia Air to be used as a booster dose- reported in September 2022.

National Medical Products Administration of China granted approval for the clinical trial application of COVID-19 mRNA vaccine- reported on Apr 03, 2022.
YS Biopharma Co., Ltd.
PIKA COVID-19 vaccine
FDA cleared the IND application for PIKA COVID-19 vaccine for a Phase 1 study.
Jiangsu Recbio Technology Co., Ltd.
Results from the Phase 2 study in the Philippines and heterologous booster vaccination Phase II study in UAE showed that ReCOV demonstrated good safety profile and excellent immune response and was able to provide definite cross-protection from the Omicron variants- reported on Nov 08, 2022.
Akston Biosciences Corporation
Top-line results from the Phase II study showed that 93% of those previously vaccinated had higher neutralizing antibody titers after a single dose of AKS-452- reported on Nov.1, 2022.
Data from an interim analysis of the Phase 2/3 study of AKS-452 showed no significant safety issues and a 91% seroconversion rate at Day 56- reported on June 24, 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream Amazon.com Inc. plans to spend more than $1 billion annually to produce movies that will get a theatrical release, Bloomberg reported, citing people familiar with the matter. The online retailer giant, which acquired movie maker MGM Studios earlier this year for $8.45 billion, is likely to produce between 12 and 15 movies each year for movie theaters. New York-based Bentex Group has recalled various children's clothing sets due to violation of the federal lead paint and lead content ban, as well as lead poisoning risk, the U.S. Consumer Product Safety Commission said. The recall involves about 87,000 units of Bentex children's clothing sets in nine different Disney themed styles.